Updates on ankylosing spondylitis: pathogenesis and therapeutic agents

Kim, Se Hee; Lee, Sang-Hoon

doi:10.4078/jrd.2023.0041

Cited by 14 publications

(4 citation statements)

References 153 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this inference cannot be confirmed at this time and therefore needs to be continued to be complemented by future researchers. ⨁⨁ Low NOT IMPORTANT Note: CI: confidence interval; MD: mean difference 1 The included studies were at risk of bias in randomization, allocation concealment, or blinding. 2 The sample size of the included studies was small.…”

Section: Plos Onementioning

confidence: 99%

“…The sacroiliac joint characteristics of patients with AS undergo significant heterogeneity compared to healthy individuals, and the clinical pathogenesis is characterized by physiologic pain and stiffness in the lumbar, hip, and back [1]. As the disease worsens, the spinal joints of AS patients may be destroyed, and in severe cases, deformities of the spine may occur, thus limiting the patient's physical activities [2].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness of exercise intervention in relieving symptoms of ankylosing spondylitis: A network meta-analysis

Luo,

Chen,

Yan

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Background Ankylosing spondylitis(AS) is a chronic inflammatory rheumatic disease that leads to a reduced quality of life. Exercise appears to be one of the promising modes of intervention. The aim of this study was to review the available evidence and compare the effectiveness of different exercises in relieving symptoms of AS. Methods We searched the Pubmed, WOS, EMbase, CNKI, Cochrane Library, and Scopus databases. The search has spanned from the creation of the database until September 15, 2023. We extracted the first author, year of article publication, sample information, intervention, duration of intervention, and outcome indicators from the literature that met the inclusion criteria. The Cochrane Risk Assessment Tool was used to assess the risk of bias for included studies. I² was used to judge the consistency of the included studies. Egger’s test and Begg’s test were used to judge whether there was significant publication bias. Forest plots were used to compare intervention effects and SUCRA was provided to rank the effects of the interventions. This study has been registered in PROSPERO(No. CRD42024518522). Results After screening, 10 papers matched the inclusion criteria for this study, and the total sample size of the 10 papers was 623. Upon analysis, the papers included in this study did not have significant publication bias (Begg’s Test P = 0.210) and had good consistency (P>0.05). The direct comparisons showed that Running, Pilates, Stretching, Yoga, and Tai Chi were more effective interventions than traditional therapies. The effect sizes, confidence intervals, and number of studies for each intervention are shown below: Running [MD -1.90 (95% CI -3.14,-0.66) n = 1], Pilates [MD -1.70 (95% CI -2.90,-0.51) n = 1], Stretching [MD -1.54 (95% CI -2.21,-0.88) n = 4], Yoga [MD -1.24 (95% CI -2.18,-0.30) n = 1], Tai Chi [MD -0.78 (95% CI -1.44,-0.12) n = 2], Exergame[MD -0.80 (95% CI -1.99,0.39) n = 1], Swiss balls[MD -1.07 (95% CI -2.58,0.44) n = 1]. The indirect comparisons showed that the range of effect sizes for each sport intervention intersected the null line. Based on cumulative probability, the order of effectiveness of different exercises in relieving AS symptoms is Running, Pilates, Stretching, Yoga, Tai Chi, Exergame, and Swiss ball. Conclusion Running, Pilates, Stretching, Yoga, and Tai Chi provided significant relief from AS symptoms. Exergame and Swiss ball were not statistically significant in relieving AS symptoms. There were no significant differences in the effectiveness of different exercise interventions in relieving AS symptoms. Running may have the most beneficial effect on alleviating AS symptoms.

show abstract

Section: Plos Onementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effectiveness of exercise intervention in relieving symptoms of ankylosing spondylitis: A network meta-analysis

Luo,

Chen,

Yan

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…The serum levels of IL-23 and IL-17 in the peripheral blood of AS patients are markedly elevated, which is linked to the disease [ 19 , 20 ]. T cells, B cells, NK cells, and macrophages, as well as the IL-23/IL-17 axis, are all involved in the inflammatory development of AS [ 21 – 23 ]. Furthermore, results from other research have revealed that antibodies can be used as biomarkers to aid in the diagnosis and prognosis of ankylosing spondylitis.…”

Section: Introductionmentioning

confidence: 99%

The causal relationship between immune cells and ankylosing spondylitis: a bidirectional Mendelian randomization study

Fei,

Yu,

et al. 2024

Arthritis Res Ther

View full text Add to dashboard Cite

Background Ankylosing spondylitis (AS) is one of several disorders known as seronegative spinal arthritis (SpA), the origin of which is unknown. Existing epidemiological data show that inflammatory and immunological factors are important in the development of AS. Previous research on the connection between immunological inflammation and AS, however, has shown inconclusive results. Methods To evaluate the causal association between immunological characteristics and AS, a bidirectional, two-sample Mendelian randomization (MR) approach was performed in this study. We investigated the causal connection between 731 immunological feature characteristic cells and AS risk using large, publically available genome-wide association studies. Results After FDR correction, two immunophenotypes were found to be significantly associated with AS risk: CD14 − CD16 + monocyte (OR, 0.669; 95% CI, 0.544 ~ 0.823; P = 1.46 × 10−4; PFDR = 0.043), CD33dim HLA DR + CD11b + (OR, 0.589; 95% CI = 0.446 ~ 0.780; P = 2.12 × 10−4; PFDR = 0.043). AS had statistically significant effects on six immune traits: CD8 on HLA DR + CD8 + T cell (OR, 1.029; 95% CI, 1.015 ~ 1.043; P = 4.46 × 10−5; PFDR = 0.014), IgD on IgD + CD24 + B cell (OR, 0.973; 95% CI, 0.960 ~ 0.987; P = 1.2 × 10−4; PFDR = 0.021), IgD on IgD + CD38 − unswitched memory B cell (OR, 0.962; 95% CI, 0.945 ~ 0.980; P = 3.02 × 10−5; PFDR = 0.014), CD8 + natural killer T %lymphocyte (OR, 0.973; 95% CI, 0.959 ~ 0.987; P = 1.92 × 10−4; PFDR = 0.021), CD8 + natural killer T %T cell (OR, 0.973; 95% CI, 0.959 ~ 0.987; P = 1.65 × 10−4; PFDR = 0.021). Conclusion Our findings extend genetic research into the intimate link between immune cells and AS, which can help guide future clinical and basic research.

show abstract

“…Rheumatic diseases, mainly including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA), are characterized by joint involvement, chronic pain, and other systemic manifestations. [1–3] Since rheumatic diseases probably cause disability, incapacity of work, and reduction of quality of life, they remain a great challenge to global health. [4,5] Tumor necrosis factor-alpha inhibitors (TNFis), conforming to the treatment purpose of symptom relief and progression restraint, possess confirmed efficacy and are commonly recommended for the management of rheumatic diseases.…”

Section: Introductionmentioning

confidence: 99%

Patient self-reported experience and satisfaction with golimumab and etanercept treatments for rheumatic diseases: A cohort study

Xia,

Zhou,

Gao

et al. 2024

Medicine

View full text Add to dashboard Cite

Golimumab and etanercept both exhibit good efficacy in treating rheumatic diseases, while the patient self-reported measurement of treatment improvement and injection experience lacks sufficient evidence. Hence, this study aimed to compare the satisfaction with disease improvement and injection experience and the level of injection site reactions (ISRs) between golimumab-treated and etanercept-treated patients with rheumatic diseases. A total of 312 patients with rheumatic diseases were serially enrolled. Among them, 158 patients received golimumab (golimumab group); the other 154 patients were treated with etanercept (etanercept group) according to the actual disease status, physician advice, and patient willingness. Satisfaction with disease improvement was assessed using the 7-point Likert scale; satisfaction with injection experience and level of ISRs were both determined by the 5-point Likert scale. Satisfaction degrees with global injection experience (P = .025), injection device (P = .008), injection frequency (P = .010), and injection convenience (P = .003) were superior in the golimumab group to the etanercept group, while satisfaction degrees with global disease improvement, symptom relief, and speed of action did not vary (all P > .050) between the 2 groups. Discomfort (P = .005), swelling (P < .001), pain (P = .028), and burning (P = .035) levels were lower in the golimumab group than in the etanercept group. In addition, among 56 patients with a history of tumor necrosis factor inhibitor treatment before golimumab, 40 (71.4%) patients preferred golimumab to other tumor necrosis factor inhibitor. After switching to golimumab treatment, the level of ISRs in most patients was reduced or comparable. Golimumab achieves a satisfying injection experience and relieves the level of ISRs over etanercept in patients with rheumatic diseases.

show abstract

Updates on ankylosing spondylitis: pathogenesis and therapeutic agents

Cited by 14 publications

References 153 publications

Effectiveness of exercise intervention in relieving symptoms of ankylosing spondylitis: A network meta-analysis

Effectiveness of exercise intervention in relieving symptoms of ankylosing spondylitis: A network meta-analysis

The causal relationship between immune cells and ankylosing spondylitis: a bidirectional Mendelian randomization study

Patient self-reported experience and satisfaction with golimumab and etanercept treatments for rheumatic diseases: A cohort study

Contact Info

Product

Resources

About